Search
Invitrogen
Complement C9 Monoclonal Antibody (aE11)
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promotions']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.viewpromo']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promocode']}}: {{promo.promoCode}} {{promo.promoTitle}} {{promo.promoDescription}}. {{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.learnmore']}}
Additional Information:
{{banner.description}}
Product Details
MA5-33373
Applications
Tested Dilution
Publications
Product Specifications
Species Reactivity
Horse,
Human,
Pig
Host/Isotype
Mouse
/ IgG2a
Class
Monoclonal
Type
Antibody
Clone
aE11
Conjugate
Form
Liquid
Concentration
100 µg/mL
Amount
100 µg
Purification
Protein G
Storage buffer
PBS with 0.1% BSA
Contains
no preservative
Storage conditions
4°C
Shipping conditions
Ambient (domestic); Wet ice (international)
RRID
Product Specific Information
Product is supplied at 1 mL (100 µL/mL). This antibody reacts with a C9 neoantigen of the terminal complement complex (TCC).
Application Notes: Functional Assay - This antibody inhibits platelet activation by antiphospholipid antibody serum. IF - Cryosections of 10 µm were dried, fixed in acetone at 4°C for 10 min, dried and blocked for 20 min with PBSA. Positive control: Mucosa from patients with H. Pylori.
Target Information
C5b-9 membrane attack complexes are assembled from five precursor molecules in the serum. Proteolytic cleavage of C5 by C5 convertase generates C5b which initiates assembly of the C5b-9 complex. The last step of C5b-9 complex formation involves polymerization of C9 which accompanies insertion of the complex into the cell membrane. During formation of C5b-8 and C9 polymerization, neoantigens are generated which are unique to the C5b-9 complex and are not present on any of the individual native complex components. The complement regulatory proteins CD59 and complement S-protein can both prevent C5b-9 insertion into the cell membrane. The formed SC5b-9 complex is unable to attach to cells and is cytolytically inactive. C5b-9 is involved in the progression of chronic proteinuric renal disease by mediating continuous tubulointerstitial damage. Early tubulointerstitial injury in the remnant kidney can be improved when C5b-9 complex forming is abrogated.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
References (0)
Have you cited this product in a publication?
Let us know so we can reference it here.
Bioinformatics
Protein Aliases: C9 complement protein; complement component 9; Complement component C9; complement protein C9; unnamed protein product
Gene Aliases: ARMD15; C9; C9D
UniProt ID: (Human) P02748, (Horse) P48770
Entrez Gene ID: (Human) 735, (Pig) 100037951, (Horse) 100034183
cell killing
immune system process
immune response
complement activation
complement activation, alternative pathway
complement activation, classical pathway
killing of cells of other organism
innate immune response
positive regulation of immune response
protein homooligomerization
complement activation, GZMK pathway
Disclaimer
Clicking the images or links will redirect you to a website hosted by BenchSci that provides third-party scientific content. Neither the content nor the BenchSci technology and processes for selection have been evaluated by us; we are providing them as-is and without warranty of any kind, including for use or application of the Thermo Fisher Scientific products presented.
Performance Guarantee
If an Invitrogen™ antibody doesn't perform as described on our website or datasheet,we'll replace the product at no cost to you, or provide you with a credit for a future purchase.*
Learn more
We're here to help
Get expert recommendations for common problems or connect directly with an on staff expert for technical assistance related to applications, equipment and general product use.
Contact tech support